

Suboxone/Subutex - Hawaii Prior Authorization Request Form

Please complete this <u>entire</u> form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Inforr	nation								
First Name:	Last Name:				Member ID:				
Address:									
City:	State:			ZIP Co	ZIP Code:				
Phone:	DOB:			Allergi	Allergies:				
Primary Insurance Information	(if any):				-				
Is the requested medicati	on: □ New or □	Continuat	ion of Thera	apy? If continuation,	list sta	rt date: _			
Is this patient currently h	ospitalized?	Yes □ No	If recently	discharged, list disc	charge (date:			
Section B - Provider Inform	mation								
First Name:			Last Name:				M.D./D.O.		
Address:		City:			State: ZIP code:				
Phone:	Fax:			NPI #:			Specialty:		
Office Contact Name / Fax atte	ention to:				•				
Section C - Medical Inform	nation								
Medication:						Strength:			
Directions for use:						Quantity:			
Diagnosis (Please be specific	: & provide as muc	h information	as possible)			ICD-10 C	CODE:		
	F		р						
Is this member pregnant?		If yes,	what is this	member's due date? _					
Section D - Previous Med	ication Trials								
Medication Name	Strength Di		ections Dates of Therap		Reason for failure / discontinuation				
							<u>Jiminaation</u>		
Castian F. Additional info		volenetien.	of why prof	anned medications w		4	o notiontle needle.		
Section E – Additional info				der.com for a list of					
T loade forei	to the patient s	T DE at Wi	Widneprov		protein	sa alterne	atives		



Suboxone/Subutex - Hawaii Prior Authorization Request Form

Member First name:		Member Last name:	Member DOB:				
Clinical and Drug Specific Information							
ALL REQUESTS							
□ Yes □ No	Does the patient have a Diagnostic and Statistical Manual, Fifth Edition, Text Revision, (DSM-V-TR) diagnosis of opioid use disorder?						
□ Yes □ No	(If yes, check which applie	e sublingual film (2 mg buprenorphine/0.5 circumstance: e sublingual tablets	-				
CONTINUATION OF THERAPY							
□ Yes □ No	Has the patient been prescribed a buprenorphine product for the purpose of opioid use disorder maintenance therapy?						
Duessiden Ci			Data				

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.